Default company panoramic image

For-Robin Therapeutics

Our Mission: To revolutionize breast cancer therapy with our patented monoclonal antibody for direct immunotherapy and as an antibody drug conjugate..

  • Stage Product In Development
  • Industry Biotechnology
  • Location Williamsville, NY, USA
  • Currency USD
  • Founded March 2012
  • Employees 11
  • Website

Company Summary

For-Robin’s mission is to revolutionize breast cancer treatment through targeted treatment with humanized JAA-F11 monoclonal antibody. Our humanized JAA-F11 can be used directly, or since it internalizes, as an antibody drug conjugate. It will kill tumor cells and block metastasis, without causing side effects since its target, TF-Ag, is not on normal cells. JAA-F11 is protected by a U.S. patent and pending patents in Europe, Canada and Japan.


  • Default avatar
    Kate Rittenhouse-Olson, Ph.D.
    President, Chief Scientific Officer

    Dr. Rittenhouse-Olson’s training includes time as a post-doctoral fellow at Roswell Park Cancer Institute (RPCI), wherein she gained clinical tumor immunology experience with T. Ming Chu, (the discoverer of Prostate Specific Antigen for diagnosis) and then carbohydrate experience with Khushi Matta. For over 25 years her University of Buffalo (UB) laboratory has been involved in studying carbohydrate tumor associated antigens, and she has studied

  • Default avatar
    Sally Quataert, Ph.D
    Chief Regulatory Affairs

    Dr. Sally Quataert has extensive experience and expertise in the development, validation and application of immunological methods for clinical translational research and vaccine evaluation. She has over 20 years experience in industry, with experience in regulatory compliance for GLP and GMP. Quataert has lead preclinical and clinical testing programs that provided the data supporting licensure of H.infuenzae b, Streptococcus pneumoniae, Neiser

  • Default avatar
    James Olson, Ph.D.
    Chief Toxicologist

    Dr. James Olson is a University at Buffalo Distinguished Professor, with appointments in Pharmacology and Toxicology (School of Medicine and Biomedical Sciences) and Social and Preventive Medicine (School of Public Health and Health Professions), specializing in toxicology and the environmental health sciences. His research experience and expertise ranges from basic research on drug metabolism and disposition / pharmacokinetics to assessment of

  • Default avatar
    Robert Redd
    Business Advisor

    Advisor, Entrepreneur-in-Residence for UB STOR assigned For-Robin. > 30 yrs’ management experience. Successful exit of a 10 yr old telecommunications services start-up (iVergent). Ran divisions for 2 multinational companies (Outokumpu OY & Schlumberger, LTD). Bob is a Board Member of the Western NY Venture Assoc.and of BeetNPath, a steel oats ready-made meal business. A MBA (UB) and a BS in Chemistry (U of Maryland).


  • Default avatar
    Diane McMahon
    Default avatar
    The Kane Firm